SG10201709552XA - Capsid-modified, raav3 vector compositions and uses in gene therapy of human liver cancer - Google Patents
Capsid-modified, raav3 vector compositions and uses in gene therapy of human liver cancerInfo
- Publication number
- SG10201709552XA SG10201709552XA SG10201709552XA SG10201709552XA SG10201709552XA SG 10201709552X A SG10201709552X A SG 10201709552XA SG 10201709552X A SG10201709552X A SG 10201709552XA SG 10201709552X A SG10201709552X A SG 10201709552XA SG 10201709552X A SG10201709552X A SG 10201709552XA
- Authority
- SG
- Singapore
- Prior art keywords
- capsid
- modified
- gene therapy
- liver cancer
- human liver
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title 1
- 201000007270 liver cancer Diseases 0.000 title 1
- 208000014018 liver neoplasm Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4634—Antigenic peptides; polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Manufacturing & Machinery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/899,481 US9920097B2 (en) | 2007-04-09 | 2013-05-21 | Capsid-modified rAAV vector compositions having improved transduction efficiencies, and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201709552XA true SG10201709552XA (en) | 2018-01-30 |
Family
ID=51023068
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201709552XA SG10201709552XA (en) | 2013-05-21 | 2014-05-21 | Capsid-modified, raav3 vector compositions and uses in gene therapy of human liver cancer |
SG11201510757PA SG11201510757PA (en) | 2013-05-21 | 2014-05-21 | Capsid-modified, raav3 vector compositions and uses in gene therapy of human liver cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201510757PA SG11201510757PA (en) | 2013-05-21 | 2014-05-21 | Capsid-modified, raav3 vector compositions and uses in gene therapy of human liver cancer |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP2999791B1 (en) |
JP (3) | JP6628286B2 (en) |
KR (4) | KR102649543B1 (en) |
CN (3) | CN111763690A (en) |
AU (3) | AU2014274457B2 (en) |
CA (1) | CA2917018A1 (en) |
DK (1) | DK2999791T3 (en) |
HK (1) | HK1217730A1 (en) |
SG (2) | SG10201709552XA (en) |
WO (1) | WO2014193716A2 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5410017A (en) * | 1993-05-21 | 1995-04-25 | Rohm And Haas Company | Continuous thermal polycondensation process for preparing polypeptide polymers |
US9725485B2 (en) | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
US10294281B2 (en) | 2012-05-15 | 2019-05-21 | University Of Florida Research Foundation, Incorporated | High-transduction-efficiency rAAV vectors, compositions, and methods of use |
WO2015048534A1 (en) | 2013-09-26 | 2015-04-02 | University Of Florida Research Foundation, Inc. | Synthetic combinatorial aav capsid library for targeted gene therapy |
EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
WO2016126857A1 (en) | 2015-02-03 | 2016-08-11 | University Of Florida Research Foundation, Inc. | Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof |
GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
JP7064214B2 (en) | 2015-09-28 | 2022-05-10 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Methods and Compositions for Antibodies Avoidant Viral Vectors |
US20200181644A1 (en) * | 2015-10-22 | 2020-06-11 | University Of Florida Research Foundation, Incorporated | Synthetic combinatorial aav3 capsid library |
MX2018007237A (en) * | 2015-12-14 | 2018-12-11 | Univ North Carolina Chapel Hill | Modified capsid proteins for enhanced delivery of parvovirus vectors. |
CA3033125A1 (en) * | 2016-08-16 | 2018-02-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeted gene transfer |
WO2018035503A1 (en) * | 2016-08-18 | 2018-02-22 | The Regents Of The University Of California | Crispr-cas genome engineering via a modular aav delivery system |
EP3585883A4 (en) | 2017-02-21 | 2021-04-14 | University of Florida Research Foundation, Incorporated | Modified aav capsid proteins and uses thereof |
MX2020000244A (en) * | 2017-06-27 | 2020-09-28 | Regeneron Pharma | Tropism-modified recombinant viral vectors and uses thereof for the targeted introduction of genetic material into human cells. |
CA3075180A1 (en) * | 2017-09-08 | 2019-03-14 | Generation Bio Co. | Lipid nanoparticle formulations of non-viral, capsid-free dna vectors |
JP2021510539A (en) * | 2018-01-16 | 2021-04-30 | シーエルエス セラピューティクス リミテッドCLS Therapeutics Limited | Treatment of diseases by liver expression of enzymes with deoxyribonuclease (DNase) activity |
US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
EP3755795A4 (en) | 2018-02-19 | 2022-07-20 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof |
WO2019191418A1 (en) * | 2018-03-29 | 2019-10-03 | Asklepios Biopharmaceutical, Inc. | Liver tropic recombinant aav6 vectors that evade neutralization |
EP3774854A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Antibody-evading virus vectors |
EP3784697A4 (en) * | 2018-04-27 | 2022-07-06 | Spark Therapeutics, Inc. | Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same |
JP7142815B2 (en) * | 2018-06-21 | 2022-09-28 | 株式会社遺伝子治療研究所 | Adeno-associated virus virions for gene transfer into human liver |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
WO2020079256A1 (en) * | 2018-10-19 | 2020-04-23 | Genethon | Modulation, monitoring and prediction of the immune response directed against aav gene therapy vectors |
SI3911354T1 (en) * | 2019-01-18 | 2023-12-29 | Institut Pasteur | Aav-mediated gene therapy restoring the otoferlin gene |
EA202192501A1 (en) | 2019-03-21 | 2021-12-16 | Страйдбайо, Инк. | RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS |
EP3736330A1 (en) * | 2019-05-08 | 2020-11-11 | European Molecular Biology Laboratory | Modified adeno-associated virus (aav) particles for gene therapy |
EP3999120A4 (en) * | 2019-07-04 | 2024-02-21 | Childrens Medical Res Institute | Methods and aav vectors for in vivo transduction |
AU2020311618A1 (en) * | 2019-07-11 | 2022-03-03 | Centre Hospitalier Universitaire De Nantes | Chemically-modified adeno-associated virus |
WO2021076925A1 (en) | 2019-10-17 | 2021-04-22 | Stridebio, Inc. | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
US20230340526A1 (en) * | 2019-11-25 | 2023-10-26 | University Of Florida Research Foundation, Incorporated | Novel aav3b variants that target hepatocytes and evade the humoral immune response |
WO2021108468A1 (en) * | 2019-11-25 | 2021-06-03 | University Of Florida Research Foundation, Incorporated | Novel aav3b variants that target human hepatocytes in the liver of humanized mice |
TW202140791A (en) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | Methods of treating phenylketonuria |
AU2021267856A1 (en) * | 2020-05-05 | 2022-12-01 | The University Of North Carolina At Chapel Hill | Modified adeno-associated virus 5 capsids and uses thereof |
JP2023548432A (en) | 2020-11-11 | 2023-11-16 | ヨーロピアン モレキュラー バイオロジー ラボラトリー | Modified virus particles for gene therapy |
CN113647359A (en) * | 2021-08-15 | 2021-11-16 | 芜湖职业技术学院 | Construction method of tunicamycin injection induced acute liver injury mouse model |
WO2023072181A1 (en) * | 2021-10-28 | 2023-05-04 | Shanghai Vitalgen Biopharma Co., Ltd. | Adeno-associated virus capsid |
WO2023201368A2 (en) * | 2022-04-15 | 2023-10-19 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6156303A (en) * | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
EP1486567A1 (en) * | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
EP2357010B1 (en) * | 2005-04-07 | 2013-06-12 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
EP2623605B1 (en) * | 2007-04-09 | 2018-11-28 | University of Florida Research Foundation, Inc. | RAAV vector compositions having tyrosine-modified capsid proteins and methods for use |
US9725485B2 (en) * | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
CA2762118A1 (en) * | 2008-05-20 | 2010-01-28 | Eos Neuroscience, Inc. | Vectors for delivery of light-sensitive proteins and methods of use |
WO2012109570A1 (en) * | 2011-02-10 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
CN103060331B (en) * | 2012-12-05 | 2014-10-08 | 南京医科大学第一附属医院 | Preparation method and application of capsid-protein-mutant double-stranded recombinant adeno-associated virus containing mediated-membrane-stabile CD40L gene |
-
2014
- 2014-05-21 SG SG10201709552XA patent/SG10201709552XA/en unknown
- 2014-05-21 EP EP14733803.2A patent/EP2999791B1/en active Active
- 2014-05-21 CN CN202010551899.1A patent/CN111763690A/en active Pending
- 2014-05-21 WO PCT/US2014/039015 patent/WO2014193716A2/en active Application Filing
- 2014-05-21 KR KR1020227033180A patent/KR102649543B1/en active IP Right Grant
- 2014-05-21 KR KR1020217008950A patent/KR102298579B1/en active IP Right Grant
- 2014-05-21 CN CN202010039122.7A patent/CN111411125A/en active Pending
- 2014-05-21 SG SG11201510757PA patent/SG11201510757PA/en unknown
- 2014-05-21 CN CN201480041247.6A patent/CN105408486B/en active Active
- 2014-05-21 KR KR1020157036164A patent/KR102234672B1/en active IP Right Grant
- 2014-05-21 DK DK14733803.2T patent/DK2999791T3/en active
- 2014-05-21 KR KR1020217027678A patent/KR20210111878A/en not_active Application Discontinuation
- 2014-05-21 CA CA2917018A patent/CA2917018A1/en active Pending
- 2014-05-21 JP JP2016515056A patent/JP6628286B2/en active Active
- 2014-05-21 AU AU2014274457A patent/AU2014274457B2/en active Active
- 2014-05-21 EP EP18202680.7A patent/EP3492597A3/en active Pending
-
2016
- 2016-05-18 HK HK16105737.9A patent/HK1217730A1/en unknown
-
2019
- 2019-11-27 JP JP2019214352A patent/JP7021786B2/en active Active
-
2020
- 2020-01-03 AU AU2020200041A patent/AU2020200041B2/en active Active
-
2022
- 2022-01-28 JP JP2022011418A patent/JP7344595B2/en active Active
- 2022-06-17 AU AU2022204246A patent/AU2022204246A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2014274457A1 (en) | 2016-01-21 |
HK1217730A1 (en) | 2017-01-20 |
WO2014193716A2 (en) | 2014-12-04 |
DK2999791T3 (en) | 2019-03-18 |
CN105408486A (en) | 2016-03-16 |
EP3492597A3 (en) | 2019-08-28 |
JP7344595B2 (en) | 2023-09-14 |
KR102649543B1 (en) | 2024-03-21 |
JP2016520311A (en) | 2016-07-14 |
EP2999791B1 (en) | 2018-12-05 |
AU2020200041B2 (en) | 2022-03-17 |
KR102234672B1 (en) | 2021-04-06 |
WO2014193716A3 (en) | 2015-01-22 |
KR102298579B1 (en) | 2021-09-07 |
AU2014274457B2 (en) | 2019-10-24 |
KR20220136477A (en) | 2022-10-07 |
JP6628286B2 (en) | 2020-01-08 |
JP2022068181A (en) | 2022-05-09 |
EP2999791A2 (en) | 2016-03-30 |
EP3492597A2 (en) | 2019-06-05 |
JP2020048571A (en) | 2020-04-02 |
KR20160010617A (en) | 2016-01-27 |
JP7021786B2 (en) | 2022-02-17 |
CA2917018A1 (en) | 2014-12-04 |
SG11201510757PA (en) | 2016-01-28 |
KR20210111878A (en) | 2021-09-13 |
CN111763690A (en) | 2020-10-13 |
CN105408486B (en) | 2020-07-14 |
KR20210037001A (en) | 2021-04-05 |
AU2020200041A1 (en) | 2020-02-06 |
CN111411125A (en) | 2020-07-14 |
AU2022204246A1 (en) | 2022-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1217730A1 (en) | Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer raav3 | |
IL273090B (en) | Methods and compositions for the treatment of cancer | |
HK1226301A1 (en) | Modified therapeutic agents and compositions thereof | |
IL286759A (en) | Therapeutic methods and compositions | |
SG10201801433XA (en) | Composition and vaccine for treating prostate cancer | |
EP2943565A4 (en) | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse | |
HK1211832A1 (en) | Novel compositions and uses of anti-hypertension agents for cancer therapy | |
IL238177A0 (en) | Methods and compositions for the treatment of cancer | |
EP3193914A4 (en) | Organ protection in psma-targeted radionuclide therapy of prostate cancer | |
EP2968474A4 (en) | Skin compositions and uses | |
EP2884984A4 (en) | Therapeutic compositions and methods | |
EP2961419A4 (en) | Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy | |
SG11201508167PA (en) | Therapeutic compositions and uses thereof | |
EP3049536A4 (en) | Methods and compositions relating to cancer therapy with dna damaging agents | |
EP3004396A4 (en) | Methods and compositions for the treatment of cancer | |
ZA201604370B (en) | Prostate cancer gene profiles and methods of using the same | |
HK1252038A1 (en) | Gene expression profiles and uses thereof in breast cancer | |
EP3044590A4 (en) | Methods and compositions for tumor vasculature imaging and targeted therapy | |
EP2958591A4 (en) | Methods and compositions relating to the treatment of cancer | |
EP3010504A4 (en) | Methods and compositions to treat cancer | |
EP2852370A4 (en) | Radiance compositions and methods of use | |
EP2928456A4 (en) | Methods and compositions for treatment of cancer | |
EP2895186A4 (en) | Therapeutic compositions and related methods | |
EP2744786A4 (en) | Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer | |
HK1207328A1 (en) | Application of icaritin in preparing medicament for treating primary liver cancer |